

| Drug common name | Iberdomide |
| INN | iberdomide |
| Description | Iberdomide is an experimental thalidomide analog that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers and was also tested in people with lupus.
|
| Classification | Small molecule |
| Drug class | thalidomide derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1 |
| PDB | — |
| CAS-ID | 1323403-33-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989927 |
| ChEBI ID | — |
| PubChem CID | 67335295 |
| DrugBank | DB12101 |
| UNII ID | 8V66F27X44 (ChemIDplus, GSRS) |

